Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
February 11, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and reviewed recent business highlights.
“We’re very pleased with the 2020 commercial performance for our marketed products, and expect steady and continued growth in 2021 across our product portfolio, driven by improved disease awareness, new patient finding, and geographic expansion. In the fourth quarter we celebrated the regulatory approvals of our third and fourth commercial medicines: OXLUMO, in the EU and U.S.; and Leqvio, in the EU. We also reported positive topline results from the HELIOS-A Pha